NeuroPace (NPCE) Short term Debt (2020 - 2021)
NeuroPace's (NPCE) quarterly Short term Debt came in at $3.6 million in Q1 2021, up 75.72% quarter-over-quarter from $2.0 million in Q4 2020.
NeuroPace (NPCE) Short term Debt (2020 - 2021) Analysis & Trends
NeuroPace's Short term Debt history runs 2 years deep, the most recent figure standing at $3.6 million for Q1 2021.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $3.6 million in Q1 2021; TTM through Mar 2021 was $3.6 million, a N/A change from a year earlier, with the FY2020 full-year figure at $2.0 million, changed N/A from the prior year.
- Short term Debt improved to $3.6 million in Q1 2021 per NPCE's latest filing, from $2.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $3.6 million in Q1 2021 and bottomed at $2.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 3.59 Mn |
| Dec 31, 2020 | 2.04 Mn |